Replicel Life Sciences Inc represents values of innovation, integrity, and patient-centricity. As a biotechnology company, Replicel aims to develop and commercialize autologous cell therapies for the treatment of chronic conditions, such as hair loss, tendinosis, and skin aging. With a focus on regenerative medicine, Replicel's corporate philosophy revolves around advancing medical research and providing effective and safe treatments for patients. By combining cutting-edge technology and scientific expertise, Replicel strives to improve the quality of life for individuals suffering from various ailments.

Replicel Life Sciences Inc is primarily present in Canada, the United States, and Germany.

Replicel Life Sciences Inc has achieved significant milestones in its journey. Since its inception, the company has made notable progress. Some of the key milestones include successful completion of phase I clinical trials for its RCH-01 product, which demonstrated positive safety and efficacy results. Replicel also obtained regulatory approvals for its clinical trials in various countries, further validating its innovative technologies. Furthermore, the company has forged strategic partnerships and collaborations with renowned institutions and pharmaceutical companies, enhancing its position in the market. These milestones showcase Replicel's commitment to advancing regenerative medicine and its potential to revolutionize the treatment of various conditions.

Replicel Life Sciences Inc. is a leading biotechnology company specializing in regenerative medicine and cell therapy. Founded in 2002, the company focuses on developing innovative treatments for chronic diseases and conditions using a patient's own cells. With a strong emphasis on research and development, Replicel has made significant advancements in the field of cellular therapy. The company has collaborated with renowned scientists and academic institutions to bring its groundbreaking technologies to the market. By harnessing the potential of cell-based therapies, Replicel Life Sciences Inc. aims to revolutionize the way we treat various medical conditions.

Some of the main competitors of Replicel Life Sciences Inc in the market are Histogen Inc, Juventas Therapeutics Inc, and RepliCel Life Sciences Inc.

Replicel Life Sciences Inc primarily operates in the biotechnology and life sciences industry.

The business model of Replicel Life Sciences Inc is focused on the development of autologous cell therapies for treating various conditions such as chronic tendinosis, androgenetic alopecia (pattern baldness), and aging and sun-damaged skin. Replicel utilizes a unique technology called the dermal sheath cup (DSC) cells to isolate and replicate a patient's own cells, which are then reintroduced into the affected area to stimulate tissue repair and regeneration. By leveraging the body's natural healing capabilities, Replicel aims to provide effective and personalized treatments for individuals looking to address these specific conditions.

KGV kan i øjeblikket ikke beregnes for Replicel Life Sciences.

KUV kan i øjeblikket ikke beregnes for Replicel Life Sciences.

AlleAktien Kvalitetsscore for Replicel Life Sciences er 2/10.

Omsætningen kan i øjeblikket ikke beregnes for Replicel Life Sciences.

Overskuddet kan i øjeblikket ikke beregnes for Replicel Life Sciences.

Replicel Life Sciences Inc. is a Canadian biotechnology company specializing in the development of technologies for hair and skin regeneration. The company was originally founded as Tryton Medical Inc. and focused on the development of medical devices for the treatment of arterial narrowing. In 2010, the company acquired the cell replication technology from RepliCel Life Sciences Inc. and changed its name to Replicel Life Sciences Inc. Since then, the company has expanded its activities into regeneration research and focuses on the development of products for the treatment of hair loss and skin aging. Replicel Life Sciences consists of two divisions. The first division is hair restoration, where Replicel has developed a process called Autologous Cell Implantation (ACI). This process involves extracting hair follicle cells from the patient's head, cultivating and multiplying them in a laboratory, and then injecting the cultivated cells into the affected hair follicles of the patient to stimulate the growth of new hair. The ACI procedure has the potential to serve a large market, as up to 80% of men and women are affected by hair loss over the course of their lives. The second division of Replicel Life Sciences is skin regeneration, where the company is working on the development of products that promote natural skin regeneration. The company has developed a micro-needle technology called RCI-02, which stimulates the collagen of the skin. It is expected that this technology will improve skin elasticity and contribute to a more youthful appearance. Another product from Replicel, called RCS-01, is a cell therapy for the restoration of collagenous tissue. The therapy is intended to reduce wrinkles and scars. Due to Replicel's business being based on cryopreservation and cultivated cell therapy, extensive research and development activities are required to ensure that the produced cell therapies and their components are safe and effective. For this reason, the company employs a team of scientists and experts in the field of molecular biology, stem cell biology, and dermatology to ensure that its products meet the highest quality standards. Replicel Life Sciences follows a licensed business model and has established partnerships with various organizations to bring its products to market. In October 2015, the company acquired an exclusive license for the commercial exploitation of its cell therapy products in Japan through Shiseido Company Limited. Shiseido will support Replicel in the marketing and commercialization of ACS-05 and RCS-01 in the Japanese markets. Replicel has also formed a partnership with the European regulatory authority EMEA (European Medicines Agency) to obtain approval for its stem cell therapy. In conclusion, Replicel Life Sciences has a unique business model based on the exploration of cell therapies for hair and skin regeneration. It has developed a wide range of products and has excellent partnerships for the global marketing of its products. The future of Replicel looks promising as the demand for innovative therapeutic solutions for hair and skin regeneration continues to grow.

Replicel Life Sciences udbetaler et udbytte på 0 CAD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Replicel Life Sciences, eller selskabet udbetaler ikke udbytte.

ISIN'en for Replicel Life Sciences er CA76027P4006.

WKN for Replicel Life Sciences er A2APX7.

Tickeren for Replicel Life Sciences er RP.V.

I løbet af de sidste 12 måneder betalte Replicel Life Sciences en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Replicel Life Sciences sandsynligvis betale en dividende på 0 CAD.

Udbytteafkastet for Replicel Life Sciences er i øjeblikket .

Replicel Life Sciences betaler kvartalsvis udbytte. Dette uddeles i månederne .

Replicel Life Sciences betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 CAD. Dette svarer til et dividendeafkast på 0 %.

Replicel Life Sciences bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Replicel Life Sciences fra den 5.8.2024 på 0 CAD, skulle du have haft aktien i din portefølje før ex-datoen den 5.8.2024.

Udbetalingen af det sidste udbytte blev foretaget den 5.8.2024.

I løbet af 2023 udbetalte Replicel Life Sciences 0 CAD i form af dividender.

Udbytterne fra Replicel Life Sciences udbetales i CAD.